Hirayama, Takeshi <br/><br/>
Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.  [electronic resource] 

 -  Internal medicine (Tokyo, Japan)  May 2018 
 - 1219-1227 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1349-7235 
<br/><br/><label>Standard No.: </label>10.2169/internalmedicine.9479-17  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anilides--therapeutic use<br/>Antiviral Agents--therapeutic use<br/>Carbamates--therapeutic use<br/>Case-Control Studies<br/>Cyclopropanes<br/>Cytochrome P-450 CYP3A--metabolism<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepatitis C--drug therapy<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Hydroxycholesterols--blood<br/>Imidazoles--therapeutic use<br/>Interferons--administration & dosage<br/>Isoquinolines--therapeutic use<br/>Lactams, Macrocyclic<br/>Macrocyclic Compounds--therapeutic use<br/>Male<br/>Middle Aged<br/>Proline--analogs & derivatives<br/>Pyrrolidines<br/>Ritonavir--therapeutic use<br/>Sex Factors<br/>Sulfonamides--therapeutic use<br/>Treatment Failure<br/>Valine--analogs & derivatives